LEADER 04181nam 2201129z- 450 001 9910557741603321 005 20210501 035 $a(CKB)5400000000045926 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68974 035 $a(oapen)doab68974 035 $a(EXLCZ)995400000000045926 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRole of Genomics in the Management of Hypertension 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (200 p.) 311 08$a3-03936-627-0 311 08$a3-03936-628-9 330 $aArterial hypertension affects about 1 billion people worldwide and it is the strongest modifiable risk factor for cardiovascular disease and related disability. Since the initial discovery of rare monogenic disorders with large effects, the role of genomics has evolved into large genome-wide association studies detecting common variants with a modest effect size. Similarly, pharmacogenomics has emerged as a new tool for understanding variability in drug response, to maximize efficacy and reduce toxicity. This book presents the most recent advances in the field of genetics and genomics of arterial hypertension and their potential impact on clinical management. The book is a useful tool for clinicians but also to the research community and those who want to be updated in the field. 606 $aBiology, life sciences$2bicssc 606 $aResearch & information: general$2bicssc 610 $aadducin 610 $aAfrican American 610 $aaldosterone 610 $aaldosterone-producing adenoma 610 $aARMC5 610 $aatrial natriuretic peptide 610 $ablood pressure 610 $aburden test 610 $aCACNA1D 610 $acardiac hypertrophy 610 $acardio-tonic steroids 610 $acardiovascular diseases 610 $acervical artery dissection 610 $aCRY1 610 $aCRY2 610 $aDNA methylation 610 $aendocrine hypertension 610 $aendogenous ouabain 610 $aendothelial cells 610 $aendothelial dysfunction 610 $aepigenetics 610 $aessential hypertension 610 $aexome microarray 610 $afibromuscular dysplasia 610 $agenetic association 610 $agenetics 610 $agenetics of left ventricular hypertrophy 610 $agenome-wide association studies 610 $aGRK4 610 $aheart failure 610 $ahistone modifications 610 $aHSD3B1 610 $aHSD3B2 610 $ahypertension 610 $ahypokalemia 610 $aKruppel-like factor 15 610 $aleft ventricular hypertrophy 610 $aLiddle syndrome 610 $alow renin hypertension 610 $alow-renin 610 $amicro RNA 610 $amineralocorticoid receptor 610 $amonogenic hypertension 610 $anext-generation sequencing 610 $anon atherosclerotic vascular stenosis 610 $anon-coding RNA 610 $aPHACTR1 610 $aplatelet aggregation 610 $aprimary aldosteronism 610 $arare variants 610 $arare-variants association testing 610 $arenal damage 610 $arenin 610 $aSCNN1A 610 $aSCNN1B 610 $aSCNN1G 610 $asequence kernel association test 610 $asmooth muscle cells contraction 610 $aspontaneous coronary arteries dissection 610 $aT2238C variant 610 $atranscriptome profiing 610 $avascular smooth muscle cells 615 7$aBiology, life sciences 615 7$aResearch & information: general 700 $aMulatero$b Paolo$4edt$01329482 702 $aMonticone$b Silvia$4edt 702 $aMulatero$b Paolo$4oth 702 $aMonticone$b Silvia$4oth 906 $aBOOK 912 $a9910557741603321 996 $aRole of Genomics in the Management of Hypertension$93039499 997 $aUNINA